Dry Eye News and Research

RSS
Dry eye is one of the most common complaints seen by eye doctors, accounting for nearly one fourth of all office visits. Caused by insufficient tear production or excessive tear evaporation, dry eye can be a mild, episodic feeling of discomfort associated with certain circumstances, such as exposure to dry, hot or windy environments; however, it can also be a chronic medical condition that, if left untreated, may lead to increased risk of infection or visual impairment.
World through the eyes of a person with eye disease

World through the eyes of a person with eye disease

Isotechnika Pharma receives grant of $237,069 to support NICAM program

Isotechnika Pharma receives grant of $237,069 to support NICAM program

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

EMA validates Lux Biosciences' voclosporin MAA

EMA validates Lux Biosciences' voclosporin MAA

Corneal transplant surgery: DSAEK leads to greater cell loss overall than PKP

Corneal transplant surgery: DSAEK leads to greater cell loss overall than PKP

DSAEK cornea transplant offers potential long-term benefits

DSAEK cornea transplant offers potential long-term benefits

Isotechnika Labs amends Isodiagnostika sales agreement with Paladin Labs

Isotechnika Labs amends Isodiagnostika sales agreement with Paladin Labs

Alcon reports 2009 fourth quarter results

Alcon reports 2009 fourth quarter results

Lux Biosciences files NDA with FDA and MAA with EMA for approval of voclosporin

Lux Biosciences files NDA with FDA and MAA with EMA for approval of voclosporin

Tel Aviv University expert reviews environmental triggers of common autoimmune diseases

Tel Aviv University expert reviews environmental triggers of common autoimmune diseases

Phase 3 clinical trial results of Inspire Pharmaceuticals' PROLACRIA announced

Phase 3 clinical trial results of Inspire Pharmaceuticals' PROLACRIA announced

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

ISTA Pharmaceuticals files sNDA for bromfenac ophthalmic solution

ISTA Pharmaceuticals files sNDA for bromfenac ophthalmic solution

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

Brandeis University researchers appraises economic benefits of BOS-P lens

Brandeis University researchers appraises economic benefits of BOS-P lens

Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD

Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD

Protein content of women's saliva changes with advancing age, describe scientists

Protein content of women's saliva changes with advancing age, describe scientists

ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies

ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Patient enrollment in three late-stage clinical trials completed

Patient enrollment in three late-stage clinical trials completed